The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance

Di Ciaccio, PR; Mills, G; Shipton, MJ; Campbell, B; Gregory, G; Langfield, J; Greenwood, M; McKeague, S; Shanavas, M; Eslick, R; Kidson-Gerber, G; Smallbone, P; Tang, C; Morris, K; Bilmon, I; Yannakou, CK; Badoux, X; Berkahn, L; Farina, S; Mason, KD; Motum, P; Goss, K; Hamad, N

Author(s): Di Ciaccio, PR; Mills, G; Shipton, MJ; Campbell, B; Gregory, G; Langfield, J; Greenwood, M; McKeague, S; Shanavas, M; Eslick, R; Kidson-Gerber, G; Smallbone, P; Tang, C; Morris, K; Bilmon, I; Yannakou, CK; Badoux, X; Berkahn, L; Farina, S; Mason, KD; Motum, P; Goss, K; Hamad, N;
Details: Publication Year 2023-06,Volume 201,Issue #5,Page 887-896
Journal Title: British Journal of Haematology
Publication Type: Research article
Abstract: Lymphoma in pregnancy (LIP) presents unique clinical, social and ethical challenges; however, the evidence regarding this clinical scenario is limited. We conducted a multicentre retrospective observational study reporting on the features, management, and outcomes of LIP in patients diagnosed between January 2009 and December 2020 at 16 sites in Australia and New Zealand for the first time. We included diagnoses occurring either during pregnancy or within the first 12 months following delivery. A total of 73 patients were included, 41 diagnosed antenatally (AN cohort) and 32 postnatally (PN cohort). The most common diagnoses were Hodgkin lymphoma (HL; 40 patients), diffuse large B-cell lymphoma (DLBCL; 11) and primary mediastinal B-cell lymphoma (PMBCL; six). At a median follow up of 2.37 years, the 2- and 5-year overall survival (OS) for patients with HL were 91% and 82%. For the combined DLBCL and PMBCL group, the 2-year OS was 92%. Standard curative chemotherapy regimens were successfully delivered to 64% of women in the AN cohort; however, counselling regarding future fertility and termination of pregnancy were suboptimal, and a standardised approach to staging lacking. Neonatal outcomes were generally favourable. We present a large multicentre cohort of LIP reflecting contemporary practice and identify areas in need of ongoing research.
Publisher: Wiley
Keywords: Pregnancy; Infant, Newborn; Humans; Female; Treatment Outcome; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; *Hodgkin Disease/therapy/drug therapy; *Lymphoma, Large B-Cell, Diffuse/drug therapy; Retrospective Studies; Rituximab/therapeutic use; counselling; lymphoma; neonatology; outcomes research
Department(s): Radiation Oncology; Clinical Haematology
PubMed ID: 36880558
Publisher's Version: https://doi.org/10.1111/bjh.18727
Open Access at Publisher's Site: 10.1111/bjh.18727
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-06-22 07:56:53

Last Modified: 2024-07-10 06:32:03